8-K: Seer Reports Q4 & FY25 Results, Guides FY26 Revenue

Seer, Inc. announced its fourth quarter and full year 2025 financial results, reporting increased revenue and a reduced net loss, alongside a 2026 revenue outlook.

Summary

• Fourth quarter 2025 revenue increased 5% year-over-year to $4.2 million.
• Full year 2025 revenue grew 17% year-over-year to $16.6 million.
• Net loss for Q4 2025 was $16.0 million, an improvement from $21.7 million in Q4 2024.
• Full year 2025 net loss was $73.6 million, an improvement from $86.6 million in full year 2024.
• Installed instrument base expanded to 82, representing 67% year-over-year growth, with 33 instruments installed in 2025.
• Ended 2025 with approximately $240.6 million in cash, cash equivalents, and investments.
• Operating expenses decreased by 23% in Q4 2025 and 19% for the full year 2025, primarily due to reductions in stock-based compensation, professional services, and laboratory expenses.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report. While the company continues to operate at a loss, the significant reduction in net loss and operating expenses, coupled with strong installed base growth, indicates operational improvements and market traction despite a challenging funding environment. However, the modest 2026 revenue growth guidance tempers enthusiasm.

Positives

• Revenue growth: Q4 2025 revenue increased 5% to $4.2 million, and full year 2025 revenue increased 17% to $16.6 million.
• Improved profitability metrics: Net loss decreased to $16.0 million in Q4 2025 from $21.7 million in Q4 2024, and to $73.6 million for full year 2025 from $86.6 million in full year 2024.
• Significant operating expense reduction: Operating expenses decreased 23% in Q4 2025 and 19% for the full year 2025, driven by lower stock-based compensation, professional services, and laboratory expenses.
• Strong cash position: Ended 2025 with approximately $240.6 million in cash, cash equivalents, and investments.
• Installed base expansion: Grew installed instrument base by 67% year-over-year to 82 instruments, with 33 new installations in 2025.
• Scientific validation: Seminal customer studies published in Nature and Nature Genetics, and strong presence at the 2025 Human Proteome Organization World Congress.

Negatives

• Continued net loss: Despite improvements, the company still reported a net loss of $16.0 million for Q4 2025 and $73.6 million for the full year 2025.
• Challenging funding environment: Management noted ongoing budgetary pressures and uncertainty around NIH funding in Q4 2025.
• Modest 2026 revenue growth outlook: Full year 2026 revenue guidance of $16 million to $18 million represents only approximately 3% growth at the midpoint over full year 2025, indicating a slowdown in growth rate compared to 2025.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those expressed or implied.
• Risks include, but are not limited to, those related to expectations for future results of operations, financial position, business strategy, partnerships, adoption of products, and the outlook for fiscal year 2026.
• Ongoing budgetary pressures and uncertainty around NIH funding, as mentioned by management, pose a risk to customer spending.

Future Outlook

Seer expects full year 2026 revenue to be in the range of $16 million to $18 million, which represents approximately 3% growth at the midpoint compared to full year 2025 revenue. Management expressed confidence in opportunities for 2026 and beyond, despite a persistently challenging funding environment.

Management Comments

• "2025 was a challenging year as our customers navigated ongoing budgetary pressures, including uncertainty around NIH funding in the fourth quarter."
• "Despite this persistently challenging funding environment, we made meaningful progress across our business."
• "Our installed base grew significantly, consumable kit volume increased, the number of publications expanded throughout the year, and the Proteograph was selected to power multiple population-scale studies."
• "I am more confident than ever in our opportunities in 2026 and beyond."

Industry Context

StockSavvy.ai notes that the life sciences and proteomics industry continues to face headwinds from budgetary pressures, particularly concerning government funding like NIH grants. Seer's ability to grow its installed base and increase consumable kit volume despite these challenges suggests resilience and strong product adoption within its niche. However, the modest 2026 revenue growth guidance indicates that broader market conditions are still impacting even innovative players in the sector.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or global benchmarks within the proteomics or life sciences industry. Therefore, a direct assessment against industry standards based solely on this filing is not possible.

Related Party Transactions

• Product revenue for the full year 2025 included $5 thousand of related party revenue.
• Service revenue for the full year 2025 included $755 thousand of related party revenue.
• Cost of revenue for the full year 2025 included $61 thousand of related party cost.

Stakeholder Impact

• Shareholders: Improved net loss and reduced operating expenses may be viewed positively, but the modest 2026 revenue guidance could temper growth expectations. The strong cash position provides financial stability.
• Customers: Continued expansion of the installed base and scientific publications suggest strong product utility and satisfaction, despite budgetary pressures.
• Employees: Reduced operating expenses, particularly in areas like stock-based compensation, could impact employee incentives, though overall operational efficiency improvements might secure long-term stability.
• Suppliers: No specific impact mentioned, but reduced laboratory expenses could imply some pressure on supplier relationships or more efficient resource utilization.

Next Steps

• Host a conference call on February 26, 2026, at 1:30 pm Pacific Time / 4:30 pm Eastern Time to discuss the financial results.
• Continue to navigate ongoing budgetary pressures and uncertainty around NIH funding.
• Focus on opportunities in 2026 and beyond, including further growth in installed base, consumable kit volume, and publications.

Key Dates

Recommendation

Seer's financial results show significant improvements in reducing net loss and operating expenses, coupled with strong growth in its installed instrument base, indicating effective cost management and continued market adoption of its Proteograph platform. The substantial cash reserves provide a strong balance sheet. However, the modest 2026 revenue guidance of only 3% growth at the midpoint, alongside persistent industry-wide budgetary pressures and NIH funding uncertainty, suggests that significant top-line acceleration remains a challenge. Given the mixed signals of operational efficiency and market traction against a backdrop of slower projected growth and ongoing losses, a 'hold' recommendation is appropriate for seasoned investors awaiting clearer signs of sustained revenue acceleration and a path to profitability.

Keywords

Seer Inc., SEER, Financial Results, Proteomics, Proteograph, Biomarker Discovery, NIH Funding, Q4 2025, Full Year 2025, 2026 Outlook, Life Sciences, Biotechnology, Research Instruments, Consumables